CHNA - Loncar China BioPharma ETF
| Assets | $15.16M |
| NAV | $37.90 |
| Expense Ratio | 0.79% |
| PE Ratio | n/a |
| Beta (5Y) | 0.80 |
| Dividend (ttm) | $0.16 |
| Dividend Yield | 0.41% |
| Ex-Dividend Date | Dec 30, 2020 |
| 1-Year Return | - |
| Trading Day | April 21 |
| Last Price | $38.35 |
| Previous Close | $37.91 |
| Change ($) | 0.45 |
| Change (%) | 1.17% |
| Day's Open | 38.35 |
| Day's Range | 38.35 - 38.35 |
| Day's Volume | 320 |
| 52-Week Range | 23.73 - 42.00 |
Fund Description
The investment seeks to track the performance, before fees and expenses, of the Loncar China BioPharma Index (the index). Under normal circumstances, at least 80% of the fund's total assets (exclusive of any collateral held from securities lending) will be invested in the component securities of the index or in depositary receipts representing such component securities. The index seeks to track the performance of a modified equal-weighted portfolio of companies directly involved in the growth of China's pharmaceutical and biotech related industries. The fund is non-diversified.
| Asset Class Equity | Inception Date Aug 14, 2018 |
| Exchange NASDAQ | Ticker Symbol CHNA |
| Index Tracked LCHINA index | |
Top 10 Holdings
24.97% of assets| Name | Symbol | Weight |
|---|---|---|
| Kintor Pharmaceutical Ltd Ordinary Shares | 9939.HK | 3.23% |
| CSPC Pharmaceutical Group Ltd | 1093.HK | 2.82% |
| CanSino Biologics Inc Class H | 6185.HK | 2.82% |
| Sino Biopharmaceutical Ltd | 1177.HK | 2.63% |
| WuXi Biologics (Cayman) Inc Registered Shs Unitary 144A/Reg S | 2269.HK | 2.29% |
| Pharmaron Beijing Co Ltd Ordinary Shares - Class H | 3759.HK | 2.27% |
| Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H | 2196.HK | 2.24% |
| Shanghai Junshi Biosciences Co Ltd Class H | 1877.HK | 2.24% |
| BeiGene | BGNE | 2.23% |
| China Medical System Holdings Ltd | 867.HK | 2.21% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 30, 2020 | $0.155 | Jan 4, 2021 |
| Dec 23, 2019 | $0.04024942 | Dec 26, 2019 |
Check these China ETFs that beat the S&P 500 in the past week, which was U.S. equities?
The best pharmaceutical ETFs for Q1 2020 are KURE, CHIH, and CHNA.
Policy easing in the Chinese economy, cooling trade tensions with the United States and Beijing's efforts for more urbanization have boosted these sector ETFs in 2019.